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                                                    ABSTRACT 
Background: Asthma is the chronic disorder of airways in which many cells and cellular 
components are involved.   Asthma requiring treatment with high-dose IC, plus a second controller 
and/or SC to prevent it from becoming uncontrolled or that remains uncontrolled despite this 
therapy is termed as Severe uncontrolled asthma.The prime objective of the study was to assess the 
usefulness of Tiotropium in poorly controlled asthma patients.  
Methods: It is a retrospective and prospective observational study which was conducted in Kovai 
Medical Center and Hospital. A total of 70 patients with poorly controlled asthma were enrolled in 
this study. The assessment of asthma severity and control over the disease was measured by using 
Asthma Control Questionnaire (ACQ). The quality of life of the patients were assessed by using 
Mini Asthma Quality of Life Questionnaire (MiniAQLQ). Data were analysed by using descriptive 
and inferential statistics.  
Results: Among the 70 patients 47 were males and 23 were females. Majority of the patients were 
in the age group above 40, mostly in 61-70 age group. Most of patients had poor control or 
exacerbation of asthma due to exposure towards the occupational allergens. 55 patients had 
exposure towards allergens as part of their occupation and lead to poor control over asthma. The 
prevalence of comorbid conditions was also analysed and it was found that 31 patients were GERD 
diagnosed and 21 were not diagnosed as GERD patients but they were symptomatic and had 
frequent heart burn sensation. Tiotropium was given as step-up therapy along with ICS. 
Conclusion: In this study, patients showed significant improvement in the asthma control and 
quality of life, which was measured using ACQ and MiniAQLQ respectively. The FEV1 value 
showed significant improvement within 3 month treatment. On statistical analysis significant 
changes were observed for before and after the initiation of Tiotropium. No serious adverse effects 
were reported, only a small number of patients reported adverse effects (dry mouth). Thus from the 
study it was concluded that Tiotropium as step-up therapy along with ICS had beneficial effect on 
poorly controlled asthma patients. 
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1. INTRODUCTION 
 Asthma is the chronic disorder of airways in which many cells and cellular 
components are involved. The chronic inflammation is associated with airway hyper 
responsiveness which leads to recurrent episodes of wheezing, breathlessness, chest tightness 
and coughing, specifically at night or early in the morning. These events are typically 
concomitant with extensive, but variable, airflow obstruction within the lung which is often 
reversible instinctively or else with treatment.1 
  In asthma airway inflammation is characterized by the bronchial wall infiltration 
which is done by eosinophil, activated mast cells, and T lymphocytes. Cytokines from the T 
helper 2 cells and leukotriene’s show major role in facilitating airway inflammation, similarly 
goblet cell hyperplasia, mucus gland hypertrophy, and airway mucus accumulation are also 
seen. Other important characteristics of asthma are increased airway smooth muscle mass and 
reversible bronchoconstriction. 
 Airway inflammation, mucus accumulation, and bronchospasm account for the symptoms: 2 
1. shortness of breath 
2. wheezing 
3. cough 
4. chest tightness 
 SEVERE ASTHMA: 
 “Asthma requiring treatment with high-dose IC, plus a second controller and/or SC to 
prevent it from becoming uncontrolled or that remains uncontrolled despite this therapy” is 
termed as Severe uncontrolled asthma. 
  ATS/ERS Consensus describes severe asthma as asthma which requires treatment at 
steps 4–5 of the Global Initiative for Asthma (GINA) clinical practice guidelines. 
They are: 
  High-dose inhaled corticosteroids and a long-acting beta-antagonist, or a leukotriene 
modifier, or theophylline use in the previous year, or systemic corticosteroids for >50% of the 
                                                                                                       
Introduction 
 
Department of Pharmacy Practice 2 
 
 
last year, thereby to prevent the disease from getting uncontrolled, or the disease which 
remains uncontrolled despite all this treatment.3 
EPIDEMIOLOGY: 
 An estimated 300 million people are affected by asthma worldwide. The asthma 
global prevalence varies from 1-18% population of different countries. WHO estimated that 
due to asthma 15 million disability adjusted life years are lost annually, which symbolises 1% 
of the global disease burden. Annual deaths from asthma has been valued as 250,000 and 
mortality does not correlate with variations in prevalence within and the populations. It is 
estimated that 400 million people worldwide will be affected by 2025. Even though from the 
perspective of both patient and the society the budget to control appears high, but the budget 
of not treating asthma appropriately is even more higher.1  
SEVERE ASTHMA EPIDEMIOLOGY: 
 It fluctuates in the prevalence between one country and the another (18% in Western 
Europe, 19% in the United States and 32% in Central Europe) 3 and about 50% of these 
patients are expected to have poor control over the disease.3 In 2011 at Spain, the severe 
uncontrolled asthma prevalence, as per the medical criteria, is reported as 3.9% of all asthma 
cases. Furthermore, much higher use of resources are done by this small proportion of people 
which will be more than other asthmatic patients. Uncontrolled asthma is defined as at least 
any one of the following: 
1. There is poor control over the symptoms which are measured using questionnaires 
such as ACT and ACQ, there by which enables us to evaluate disease control .a score 
of more than1.5 and 19 for ACT are being considered as the criteria for poor control 
as per the clinical practice guidelines of GINA/National Asthma Education and 
Prevention Program (NAEPP). 
2. Frequent severe exacerbations: Requiring bursts of systemic corticosteroids for 3 or 
more days each in the previous year, because of 2 or more exacerbations. 
3. Exacerbations which requires at least 1 hospitalization, which includes ICU admission 
or need for non-invasive mechanical ventilation in the previous year. 
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4. Airflow limitation:  The FEV1 if remains <80% of predicted value even after using of 
a suitable bronchodilator and the FEV1/FVC ratio below the lower limit of normal 
(best FEV1 is >80%). 
   Inadequate control over asthma is a serious problem present, in spite of all 
advances in our understanding about the inflammatory basis of asthma and the disease 
management guidelines. Patients who are with inadequately controlled asthma have limited 
therapeutic options and they remain at high risk of serious mortality and morbidity.3 
OBJECTIVE OF ASTHMA MANAGEMENT:  
To minimize symptoms, prevent acute exacerbations and avoid adverse medication effects is 
the ultimate aim of asthma management.2 
CLASSIFICATION OF ASTHMA SEVERITY: 
Figure 1: GINA guidelines for classification of asthma severity.5 
 When previous guidelines described the ideal asthma control, the global initiative of 
asthma (GINA) guidelines provided a working scheme there by to formalise  the 
classification of asthma control. 
 Asthma is categorized as follows: 
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1. “Controlled”: patient will be having symptoms and the use of rescue medications will 
be twice per week or even less than that , night waking will be absent , activity 
limitation or airway obstruction or an exacerbation  will not be there;  
2. “Partly controlled”: the symptoms or rescue medications use will be present  for more 
than twice per week ,night waking ,activity limitation or airway obstruction or an 
exacerbation will be present in any week; 
“Uncontrolled”: the presence of any three or more of this individual characteristics 
with in any week.  
Asthma treatment, should be stepped up if the asthma is partly controlled.7   
Figure 2: shows the pictorial representation for the management of different categories of asthma 
With varying control over the disease.1 
 
  
                                                                                                       
Introduction 
 
Department of Pharmacy Practice 5 
 
 
ADVERSE EFFECTS OF STEPPING UP STEROIDS DOSE, IN UNCONTROLLED 
SEVERE PERSISTENT ASTHMA PATIENTS: 
 Cases of asthmatic Patients developing acute adrenal crisis after initiating high-dose 
inhaled fluticasone propionate therapy were reported. Acute adrenal crisis in each case were 
confirmed by investigations: 
 acute phase cortisol levels measurements, 
 glucagon stimulation test 
 short and long Synacthen stimulation tests7  
 
 Oral corticosteroids has been enormously used for over 50 years and has a major role 
in treatment of asthma, inflammatory joint disorders, and other gastrointestinal tract and 
central nervous system affecting diseases. Though effective in all such medical conditions, 
osteoporosis is the most serious adverse effect faced during this therapy. Many studies has 
reported the decline in bone mineral density during oral corticosteroid therapy. Bone loss 
occurs more rapidly in trabecular bone and it relative to dose of the therapy. 
 The risk of fracture are greater for a given degree of bone loss with oral corticosteroid 
treatment when compared with that of postmenopausal osteoporosis. 
Epidemiological studies have evaluated the relation of fracture risk with oral corticosteroids 
therapy and found out that an increase of about 50% and 100% risk is there in oral 
corticosteroid using patients.8 
 Other adverse effects due to long-term exposure towards OCSs are: 
 1. Arterial hypertension, 
2. Diabetes and metabolic syndrome 
3. Dyslipidaemia 
4. Obesity 
5. Cataracts and glaucoma 
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6. Gastrointestinal bleeds/ulcers 
7. Tuberculosis 
8. Depression 
9. Herpes 
10. Sepsis  
 Even the asthma treatment guidelines recommend that those patients who are taking 
long-term systemic OCSs have to receive preventive therapy for osteoporosis.9  
TIOTROPIUM 
  History of anticholinergic therapy perhaps was initiated in ancient Greece and India, it 
was when the wheezing patients were noted to have improvement with the inhalation of 
different belladonna plants which contains anticholinergic alkaloids. In the 1800s, atropa 
belladonna, hycoscyamus Niger and datura stramonium leaves and roots were introduced into 
the western medicine there by for the relief of respiratory symptoms like wheezing. By 
1920s, adrenergic agonists become popular as the medication of emphysema and asthma. 
Likewise, smoking anticholinergic alkaloid cigarettes which contained stramonium 
belladonna and not tobacco were also very popular for the relieve from the distress of 
bronchial asthmatic paroxysm. In the 1970s, short acting anticholinergic called as 
ipratropium bromide was developed by nadel. In 2006 Tiotropium bromide was approved for 
use in the patients with COPD.10 
 CHOLINERGIC ACTIVITY: ROLE IN THE PATHOPHYSIOLOGY OF ASTHMA: 
 Cholinergic parasympathetic nerves deliver a dominant innervation to lungs. 
Acetylcholine release from these nerves controls the airway tone, cholinergic activity and 
vasodilation. It is predominant preceder of the contraction of bronchial smooth muscle. 
Asthma patients have an increased release of acetylcholine from cholinergic nerve endings 
which leads to bronchoconstriction. The local airway inflammatory mediators with the same 
mechanism, are driving an increase in cholinergic tone. 
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Figure 3: shows the role of cholinergic activity in the pathophysiology of asthma. Autonomic regulation of the 
airway smooth muscle tone. M1, M2 , M3 represent muscarinic receptors 1, 2, 3. + and – symbols represent 
signals increasing and decreasing airway smooth muscle tone.11 
 LAMAs may be beneficial for the control of asthma, other evidences which suggest that are: 
 1)  Non-neuronal anti Inflammatory actions are there for the cholinergic antagonists 
 2) Abnormal muscarinic (M) receptor expression are present for asthmatic patients  
3) Airway hyper responsiveness are contributed by an increased cholinergic and 
smooth muscle tone. 
 MECHANISM OF ACTION OF TIOTROPIUM: 
 Tiotropium have been officially declared for the use in COPD for over 10 years, and 
the mechanism of action of the as a bronchodilator has been studied extensively in COPD. 
The release of acetylcholine from parasympathetic nerves controls airway smooth muscle 
contraction, airway tone, and vasodilation and mucus secretion through the interactions with 
the M- receptors on the airway glands, pulmonary vasculature and the smooth muscle, in the 
lungs.   M1 and M3 anticholinergic receptors blockade decrease the smooth muscle tone and 
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leads to bronchodilator, but M2 receptor inhibition has the opposite effect. Tiotropium 
dissociates more slowly from the M1 and M3 receptors, thereby making it to be a more 
potent bronchodilator. Tiotropium have a long lasting effect and a strength of clinical data in 
COPD that support its 24-hour profile, which was shown by the single dose studies.  In 
invitro and in vivo studies using experimental models for the anti-inflammatory effects of 
anticholinergics have been done. combination therapy with anticholinergics and 
corticosteroids combination therapy was found to have additive  protective effects on  the 
airway inflammation and then this effect was  investigated in guinea pig models.it was found 
that combined treatment with Tiotropium inhibits chronic allergen – induced airway 
inflammation and the followed remodelling. 
  Since acetylcholine is having a key role in pathophysiology of asthma, a clear 
validation is there for the development of anticholinergic bronchodilators as a therapy in 
asthma.11 
 
Figure 4: Shows the possible role of tiotropium bromide in the management of asthma. The colour code refers 
to the functional and clinical characteristics, that tiotropium should be able to modify according to its 
pharmacological properties. If the effect on functional and clinical asthma domains is effected prevalently by 
specific tiotropium properties, the effect on asthma control and future risk might be modulated by the 
concomitant action of different characteristics taken together. Th2, T helper-2 lymphocytes; SM, smooth muscle 
cells; MUC5AC, mucin-5 subtype AC gene; QoL, Quality of Life; ACQ-7, Asthma Control Questionnaire.12 
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   Combination of inhaled corticosteroids (ICs) along with Long-acting ß2-adrenergic 
agonists (LABAs) plays a significant role in the management of asthma. 
  But the role of long-acting anticholinergic bronchodilators (Eg, Tiotropium bromide) 
have not been fully investigated till date and therefore they are not included in the asthma 
management guidelines. 
  It is contradictory to the fact that Tiotropium have been the first drug of choice long 
acting bronchodilator for patients with chronic obstructive pulmonary disease (COPD). 
Limited use of anticholinergics in asthmatic patients are because of: 
 1. The slower onset of action  
 2. Inferior bronchodilator responses was obtained in studies comparing short-acting 
anticholinergic (ipratropium bromide) with short-acting ß2 -adrenergic agonists. 
 Studies on the efficacy of Tiotropium as maintenance therapy in asthmatic patients 
was limited. 
PURPOSE: 
 1. Significant proportion of the asthmatic patients fail to achieve control over the 
symptoms with the present treatment options including LABA even with high dose of ICSs. 
  2. There are also concerns about the safety of regular use of LABAs in patients with 
asthma.13 
  The final step recommended in the Global Initiative for Asthma (GINA) 
guidelines was the addition of another treatment, like theophylline’s, anti-IgE, 
antileukotrienes, and immunosuppressant’s (Eg, systemic corticosteroids or cyclosporine). 
Despite of all this many patients fail to attain control and they stay both symptomatic and 
obstructed.  
 An effective alternative approach for this condition is to include a second 
bronchodilator which has a difference in the mechanism of action. Thus, it signifies the 
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relevance of the use Tiotropium bromide the anticholinergic, which was shown to be 
effective in COPD patients.  
Recently Peters et al proved the beneficial effect of Tiotropium in asthmatic patients that by 
the addition of Tiotropium into low dose ICSs showed superior improvements in the morning 
and evening PEF, prebronchodilator FEV1, asthma control days and symptoms with that of 
doubling the dose of ICSs.14 
 Tiotropium has been approved in Europe since 2014 as an add-on maintenance 
treatment in therapy for adults with asthma treated with ICS/LABA and had a history of 
severe exacerbations. 
 In USA by 2015 Tiotropium was approved as once daily long-term, o maintenance 
treatment in patients of ≥12 years of age with asthma (this indication was extended in 2017 to 
include patients ≥6 years of age with asthma).15 
 Tiotropium have not been examined in a randomized controlled trial in patients with 
severe uncontrolled asthma. The aim of this study is to evaluate and validate the safety and 
efficacy of 
  Tiotropium added in asthmatic patients whose symptoms are poorly controlled with 
at least high-dose ICS plus LABA treatment (GINA step 4-5).14 
 Based on these observations, we have chosen to work on the topic “Clinical Study on 
the Usefulness of Tiotropium in Poorly Controlled Asthma Patients”. Thereby to provide 
a pathway for the better management of poorly controlled asthma patients. Research are 
enclosed in this thesis. 
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2. LITERATURE REVIEW 
 Jacqueline et al., (2018) conducted a study to describe the effect of FDA 
issued 2 main drug safety communications (DSCs) on medication dispensing 
of Tiotropium. The drug safety communication was issued in March 2008 on 
the cardiovascular safety of Tiotropium, which was a warning of a potential 
increased stroke risk and January 2010 which was an information which stated 
an absence of a significant increased stroke risk or cardiovascular events based 
on findings from a large trial. It was finally concluded that cardiovascular 
safety concerns may have affected the initiation of Tiotropium as indicated by 
the decrease in Tiotropium dispensing which was immediately shown after the 
issuing of the initial drug safety communications (DSCs).16 
 Michael et al., (2018) documented a final quantitative validating data for the 
Severe Asthma Questionnaire (SAQ). SAQ were designed to detect the impact 
of both asthma symptoms and treatment on quality of life. Finally SAQ was 
developed using the recommended qualitative and quantitative procedures for 
the scale development and thereby it can be used to gain an insight into the 
patient perceptions of how severe asthma and its treatment affects their lives.17 
 Edward et al.,(2018) conducted a study to investigate the safety and efficacy 
of glycopyrronium administered by metered dose inhaler formulated using co-
suspension delivery technology and was compared with salmeterol dry powder 
inhaler in those patients with intermittent or mild-to-moderate persistent 
asthma.it was concluded from the study that glycopyrronium metered dose 
inhaler (GP MDI) can be a major treatment option as a maintenance therapy 
for asthma.15 
 Chien et al., (2018) conducted a retrospective study at a single medical centre 
and they used the asthma control test (ACT) to assess the effectiveness of 
Tiotropium as add-on therapy in uncontrolled asthma patients. The effect of 
Tiotropium was indicated by an increase in the ACT score from the baseline 
score 3 or greater than that after 3 months add-on therapy with Tiotropium. 
From the study it was concluded that use of Tiotropium as an add-on therapy in 
patients with uncontrolled asthma is effective.39 
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 Patrick et al., (2017) conducted a retrospective cohort study on asthmatic 
patients of 18years and older to determine the relationship between oral 
corticosteroids (OCS) and the incidence of adverse effects. It was concluded 
from the results that OCS prescription may result in a cumulative burden on 
current and future health status irrespective of the dose and duration of 
treatment. Therefore to improve the  patient outcomes OCS- sparing strategies 
are extremely important.9 
 Akbar et al., (2017) conducted a study to determine the frequency of 
prescriptions for the short term use of oral corticosteroids and thereby to 
analyse the development of adverse effects such as sepsis, venous 
thromboembolism, fractures. From the study it was found out that one in five 
adults in a commercially insured plan were given prescriptions for the short 
term use of oral corticosteroids in a three year period ,along with an increased 
risk for the development of  adverse events.22 
 Josefin et al., (2017) conducted a study to investigate temporal variation in the 
Health-Related Quality of Life (HRQL) and the factors influencing the low 
HRQL, in asthmatic patients. The study was concluded with the findings that 
high educational level and knowledge on self-management paved the way 
towards higher HRQL, while overweight ,exacerbations, obesity, heart disease, 
self-rated moderate/severe disease, rhinitis and depression/anxiety were factors 
that lead to lower HRQL.36 
 Kim et al., (2016) conducted a study to analyse the relation between asthma 
exacerbations and occupational exposures this study included all the presently 
working adults (n = 1356), who reported asthma in population based- cohorts. 
Finally, from the study it was concluded that jobs handling with low molecular 
weight agents, exposure to organic dust, smoke or dust, any gas, cold, damp 
conditions, physically strenuous work were associated with inducing asthmatic 
exacerbation. Reducing such occupational exposure can help to reduce the 
exacerbation of asthma.40 
 Pierluigi et al., (2015) conducted a study to examine the safety and efficacy of 
once daily Tiotropium respimat and it was compared with placebo respimat as 
anadd on therapy to low- to medium – dose ICS for adults with symptomatic 
asthma. Once- daily dosing of Tiotropium improved the lung function after 12 
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week treatment when compared with placebo. Finally Tiotropium respimat was 
found to be a efficacious bronchodilator when used as an add on therapy for 
adult patients with not fully controlled ,mild to moderate asthma.18 
 Carolina et al.,(2015) this study was done to attempt classification of various 
manifestations of severe uncontrolled asthma ,a proposal for stepwise 
diagnostic procedure and phenotype-targeted treatment, since new data’s  made 
on asthma need to be reviewed, analysed and incorporated into the guidelines 
according to the level of evidence and recommendation.3 
 Wang et al., (2015) this study was done to evaluate the best second-line 
treatments for patients having uncontrolled moderate asthma. After the add on 
therapy for 4 and 12 weeks, the average daily diurnal peak expiratory flow 
(PEF) variability, the concentration of exhaled nitric oxide (eNO) and asthma 
control test (ACT) scores were measured. Patients were divided into 3 groups, 
which was given different add on treatments. The groups were Tiotropium 
bromide group, monteleukast sodium group and double dose inhaled 
corticosteroid (ICS) group. Finally it was concluded that Tiotropium in 
combination with ICS plus LABA showed the similar effects with double-dose 
ICS plus LABA, without any adverse effects , this was estimated to be a best 
option for optimal control of asthma.19 
 Jeannette et al., (2014) conducted a study to examine the use of Nijmegen 
Clinical Screening Instrument (NCSI) in comparison with the Asthma Control 
Questionnaire (ACQ) and Asthma Quality of Life Questionnaire (AQLQ) in 
severe asthmatic patients. Severe areas it will provide a comprehension on the 
patient requirements since it determines the burden of disease. The Nijmegen 
Clinical Screening Instrument (NCSI) was developed recently for use in 
clinical practice for COPD patients and thereby it gives a detailed picture of 
the patient’s physiological functioning, symptoms, functional impairments and 
quality of life. From the study it was understood that NCSI, ACQ and AQLQ 
measures the highly relevant aspects of health status of the severe asthmatic 
patients. But NCSI was found to measure more aspects of health status which 
were  not covered by the ACQ and AQLQ.20 
 Eric et al., (2014) performed a systematic network meta-analysis to analyse 
the magnitude of AQLQ and ACQ responses obtained with frequently used 
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asthma drugs and elements influencing these end points. It was concluded from 
the analysis that in addition to reporting the changes in mean of the 
instruments, other measurement criteria’s should also be considered, along 
with analyser responder.21 
 Kai et al., (2014) conducted a study to assess the safety and efficacy of three 
different doses of Tiotropium respimat, as an add on therapy with ICS in 
patients with moderate persistent asthma. From the study it was observed that 
Tiotropium-Respimat once daily dose improved the lung function, it was 
effective and safe as an add-on therapy for moderate persistent asthmatic 
patients. And among the three doses studied (5,2.5,1.25µg) greater 
improvement was observed in 5µg Tiotropium Respimat group.41 
 Francois et al., (2013) conducted a study with an objective to assess the 
agreement between five specific questionnaires. From the study it was 
concluded there existed only a moderate agreement between the most 
commonly used five asthma control questionnaires. The GINA score has 
shown the lowest percentage of controlled and then the highest percentage of 
uncontrolled asthma, which depicted that all these scores do not evaluate the 
same symptoms.24 
 Spears et al., (2013) conducted an exploratory study to examine whether 
smoking in asthma is associated with elevated levels of corticosteroid resistant 
sputum cytokines. In the study blood and sputum cytokine concentrations in 
never, ex and current smokers with asthma were analysed before and after oral 
corticosteroids. It was concluded from the study that cigarette smoking in 
asthma lead to corticosteroid insensitivity increase in multiple airway 
cytokines, while distinct airway cytokines were present in current smokers and 
never smokers with asthma. Several plasma cytokines were lower in smokers 
with asthma compared to never smokers with asthma.42 
 Huib et al.,(2012) conducted a to study the safety and efficacy of Tiotropium 
in patients who have frequent exacerbations and persistent airflow obstruction 
even after the treatment with inhaled glucocorticoids and long acting beta 
agonists (LABAs). From the study it was concluded that the addition 
Tiotropium significantly increased the time to the first severe exacerbation and 
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provided an effective bronchodialation, in patients with poorly controlled 
asthma even after the usage of inhaled corticosteroids and LABAs.25 
 Bateman et al., (2011) conducted a study to compare the safety and efficacy of 
long acting anticholinergic Tiotropium with salmeterol and placebo which 
were added to an ICS in B16-Arg/Arg patients with asthma which were not 
controlled by ICSs therapy alone. From the study it was concluded that long 
term anticholinergic drug, Tiotropium was noninferior to salmeterol and 
superior to placebo in moderate asthmatic patients with B16-Arg/Arg genotype 
which were not under control by ICSs therapy alone. Thus the study has shown 
the evidence for that Tiotropium can be used as an effective alternative for 
patients uncontrolled severe asthma under the ICSs and LABAs.13 
 Bernd et al., (2011) conducted a study to compare the efficacy and safety of 2 
different doses of Tiotropium doses administered through respimat inhaler with 
placebo as a step up therapy in patients with severe uncontrolled asthma, even 
after the treatment with a high dose inhaled corticosteroid and a long acting ß2- 
agonist. At the end of the study it was concluded that the addition of once daily 
Tiotropium in severe uncontrolled asthmatic patients along with a high dose 
inhaled corticosteroid plus long acting ß2 adrenergic agonist improved lung 
function remarkably.14 
 Stephen et al., (2010) conducted a study to evaluate the effectiveness of 
addition of Tiotropium bromide as a step-up therapy for patients with severe 
uncontrolled asthma in low dose inhaled glucocorticoids. Currently available 
treatment options available for severe uncontrolled asthma on low dose inhaled 
glucocorticoid are addition of leukotriene modifier, the addition of LABAs, or 
increasing the dose of inhaled glucocorticoid. As per the guidelines of National 
Asthma Education and Prevention Program encourages the last two steps. But 
recently FDA has questioned the safety of administering LABA and suggested 
strategies for minimising there use. Therefor an urge for and effective 
alternative arise. Finally from the study it was concluded that the use of 
Tiotropium as a step-up therapy showed superior effect with that of doubling 
the dose of inhaled corticosteroids and it equivalent to the addition of LABAs 
in patients with inadequately controlled asthma.26 
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 Carla et al., 2009 conducted a retrospective study to assess prevalence of 
comorbidities in severe asthma patients. From the study it was concluded that 
rhinitis and gastro oesophageal reflux disease were the most commonly 
observed comorbidity. So the severe asthmatic patients should be analysed for 
the comorbid diseases as cause for the worsened respiratory symptoms and 
uncontrolled asthma.43 
 Bateman et al., (2008) has published a comprehensive workshop report “A 
Global Strategy for Asthma Management and Prevention” and in that it 
recommends a change in approach towards asthma management with asthma 
control rather than asthma severity should be the focus of treatment decisions. 
It emphasizes the importance of self-guided management, patient care givers 
partnership in controlling asthma and also the importance of setting goals for 
the treatment.1 
 Helena et al., (2008) conducted a retrospective cross-sectional study by using 
the health databases in a Canadian province with about 1 million population. In 
this study the 6 quality-of-care among the asthmatic individuals were assessed. 
The result obtained from the study was in 18% there was poor symptom 
control, about 37% of people with poor control were not dispensed with ICS, 
while 40% received potentially inadequate doses. Hospital admission because 
of asthma was higher in the age group 6-9 years and females aged 20-44 years. 
Males and adult in the age group 20-44 years had worst asthma quality care for 
the examined 4 indicators. It was concluded from the study that suboptimal 
asthma management can be improved through the increased use of ICS and 
preventer medications and consensus guidelines recommended a decline on the 
dependence short acting ß- agonist medications.37 
 Mary et al., (2008) conducted a study to evaluate the effects of smoke free law 
on the emergency department visit rate for asthma. The study showed decrease 
in emergency department visit rate associated with asthma, because of the 
smoke free law.44 
 Tom et al., (2007) conducted a study to evaluate the effects of the reducing the 
inhaled steroid dose plus salmeterol, or salmeterol and Tiotropium. It was 
concluded that there is a role for Tiotropium in controlling severe asthmatic 
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patients ,they may enable reduction in the dose of inhaled corticosteroids and 
there causing a decline the adverse effects.23 
 Mortimer et al., (2006) performed a case control study using computerised 
general practice data from The Health Improvement Network, thereby to 
quantify the relation between adrenal insufficiency and inhaled and oral 
corticosteroid exposure. From the study it was concluded that the people 
prescribed with oral or inhaled corticosteroid are at a dose related increased 
risk for adrenal insufficiency and it also suggested that increased risk for 
people prescribed with inhaled corticosteroids were because of oral 
corticosteroid exposure. At the same time it was suggested that inhaled 
corticosteroid may have effect if they are taken in high doses.27 
 Elizabeth et al., (2005) conducted a study with an aim to analyse three 
shortened versions of ACQs measurement properties and to determine whether 
the usage of shortened versions will cause any alteration in the results of the 
clinical trial. From the study it was concluded that this three shortened versions 
of ACQ can be used for large clinical trials without causing any loss in validity 
and change in the interpretation.28 
 Nicole et al., (2005) conducted a study with objective to evaluate the relation 
between occupational exposures and severity of asthma. The methodology of 
the study was to perform an epidemiological study on the genetics and 
environment of asthma combined with a case control study with a family study 
of relatives of the asthmatic patients. Finally from the results it was suggested 
that a strong deleterious role of occupational asthmogens in severe asthmatic 
patients. And therefore it was concluded that the clinicians should consider 
occupational exposure in patients with moderate to severe asthma.29 
 Eric et al., (2004) conducted a one year prospective trial, Gaining Optimal 
Asthma control, thereby to compare the efficacy of two recommended 
controller therapies. That is an increasing dose of fluticasone propionate alone 
or in combination with long acting ß2 agonist salmeterol to achieve asthma 
control as defined in the Global Initiative for Asthma/National Institutes of 
Health guidelines. This study was very significant since till date no studies 
have done to evaluate the benefits of aiming for achieving a complete, 
comprehensive and sustained clinical control over asthma in a controlled study 
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that allows to perform dose escalation which is essential to achieve this. From 
the study it was concluded that guideline defined asthma control could be 
achieved in patients with uncontrolled asthma with a combination of 
salmeterol/fluticasone propionate.30 
 Stephen et al., (2003) conducted a study to investigate the relation between the 
sensitization and exposure towards the indoor allergens such as dust, mite, cat, 
and dog in home. Their relation on pulmonary function, exhaled nitric oxide 
(eNO) and the airway reactivity were studied. The study showed that asthmatic 
patients when exposed to allergens in home to which they were sensitized will 
be having a more severe form of the disease.45 
 Todd et al., (2002) conducted a survey on adrenal crisis in relation with intake 
of inhaled corticosteroids and find out the frequency of the side effect in 
United Kingdom. In this study the questionnaires was sent to all consultant 
paediatrician and endocrinologists registered with an enquiry that whether they 
have come across any asthmatic patients with acute adrenal crisis due to the 
use ICSs. From the study it was found out that the frequency of acute adrenal 
crisis was greater than what was expected as the majority of the patients were 
treated with ICSs doses as per the British Guidelines on Asthma Management. 
And it was found out that fluticasone despite being the least prescribed and 
most recently introduced ICSs was responsible for 94% of acute adrenal crisis , 
therefore it was suggested that until adrenal function has been assessed patients 
receiving high dose ICS should not have this therapy and should be suddenly 
stopped as this could lead to acute adrenal crisis.31 
 Walsh et al., (2001) conducted a study to find out the adverse effects of oral 
corticosteroids in relation to dose in patients with lung disease. They conducted 
a two part cross sectional study in which they matched the adverse effects in 
patients taking oral corticosteroids and control subjects, then associated the 
adverse effect to corticosteroid dose in the patient group. From the study it was 
concluded that we should encourage policies to prevent the adverse effects and 
help rational prescribing of these valuable and most widely used drugs, 
because the adverse effects were strongly related to the oral cumulative dose of 
prednisolone taken.32 
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 Juniper et al., (2001) conducted a study to find out that whether the exclusion 
of forced expiratory volume in 1 sec (FEV1) and ß2 –agonist queries from the 
seven item asthma control questionnaire will cause a variation in the 
measurement properties and validity of asthma. Finally, it was found that such 
study results will be only helpful to apply ACQ in clinical trials and 
epidemiological surveys. They cannot be used for interpretation in the 
estimation of asthma control in the individual patients, because international 
guidelines on the management of asthma control in individual patients 
recognises all three factors (symptoms, airway calibre and rescue ß2 – agonist) 
are important in the identification and estimation of asthma control since the 
patients will be showing a wide variation in the in adequacy of asthma control. 
In large studies we are excluding the measurement of FEV1 and ß2 – agonist 
use from the asthma control assessment are that in a large group studies the 
patient effect of heterogeneity is lost. Thus, it was concluded that asthma 
symptoms alone can be used to estimate the asthma control in large studies, 
thereby it will help the investigators to improve the efficiency of data 
collection and also for those who do not have access to estimate the airway 
calibre or inhaled ß2 agonist use.33 
 Van et al., (2000) conducted a study with an objective to evaluate the fracture 
risk of patients exposed to oral corticosteroids in a representative general 
medical practice. The study data’s were collected from General Practice 
Research Database (GPRD) which consist of the computerised medical records 
of the general practioners (GP). In the conclusion it results indicated an 
increased risk of fractures during oral corticosteroid treatment with an 
increased effect on the hip and vertebral body than that on the fore arm. This 
fracture risks increased shortly after the initiation of oral corticosteroid 
treatment which was reversed to the baseline after the discontinuation of oral 
corticosteroids.8 
 O’Byrne et al., (1999) conducted a study with an aim to develop and validate 
Asthma Control Questionnaire (ACQ). From the study it was observed that 
asthmatic patients who had stable clinic visit, reliability of the ACQ was high. 
The questionnaire were quite responsive for asthma control. Thus it was 
concluded that Asthma Control Questionnaire has a strong evaluative and 
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discriminative properties and therefore it can be used with confidence to 
measure asthma control.34 
 Brian et al., (1999) conducted a study with an objective to appraise the data on 
systemic adverse of the inhaled corticosteroids. The conclusion obtained from 
the results was that all inhaled corticosteroids exhibit dose related systemic 
adverse effects, even if it is lesser when compared to the dose of oral 
corticosteroids. The meta-analysis has shown that fluticasone propionate 
exhibits greater dose-related systemic bioactivity when compared other 
available inhaled corticosteroids at doses specifically above 0.8 mg/d. however 
we can minimise the long term systemic burden by introducing the lowest 
possible maintenance dose that is relative to the optimal asthmatic control and 
quality of life.35 
 Juniper et al., (1999) conducted a 9 week observational study of 40 adults 
with symptomatic asthma for the development and validation of the 
MiniAQLQ. From the study it was concluded the Mini Asthma Quality of Life 
Questionnaire showed good measurement properties but were not as strong as 
that of Original Asthma Quality of Life Questionnaire. So the selection of 
questionnaire for analysing quality of life depend on the type of study.38 
 Susan et al., (1999) conducted a prospective study to examine the prevalence 
of GERD in asthma patients without reflux symptoms. The study suggested 
that GERD is present in asthma patients even in the absence of oesophageal 
symptoms.46 
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3. AIM & OBJECTIVES 
AIM: 
• To study the usefulness of Tiotropium in poorly controlled asthma patients. 
OBJECTIVES:  
• To study the beneficial effect of Tiotropium in poorly controlled asthma 
patients. 
• To assess the adverse drug effects of Tiotropium. 
• To assess the effect of Tiotropium in Pulmonary Function Test. 
• To assess the asthma control and severity in poorly controlled asthma 
patients using Asthma Control Questionnaire (ACQ) and the beneficial 
effect of Tiotropium on it. 
• To assess the quality of life of poorly controlled asthma patients and the 
beneficial effect of Tiotropium in the quality of life using Mini Asthma 
Quality of Life Questionnaire (MiniAQLQ). 
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4. METHODOLOGY 
 
STUDY DESIGN: 
  Retrospective and Prospective Observational Study 
 
STUDY SITE: 
  Kovai Medical Centre and Hospital KMCH; Avinashi Road, 
Coimbatore – 14 
 
STUDY DURATION: 6 month (February – July)  
    
STUDY POPULATION: 
  A total of 70 patients were included in this study. 
 
STUDY CRITERIA: 
Inclusion Criteria: Any poorly controlled asthmatic patients aged 18 years and 
above receiving and had received TIOTROPIUM will be included in the study. 
 
Exclusion Criteria: Pregnant women,chronic obstructive pulmonary disorder 
(COPD)patients,  Heart Failure patients will be excluded from the study. 
 
STUDY TOOLS / SOURCE DOCUMENTS: 
Data collection: A specially designed data collection form will be utilized to collect 
patient’s demographic details ,past and present medical conditions 
,diagnosis,laboratory data and prescribed medications and all other details required for 
the study. 
 
ASTHMA CONTROL QUESTIONNAIRE (ACQ): To assess the patients control 
over asthma and to determine severity of asthma,this questionnaire was used. It is a 
validated questionnaire and it has scoring system. The responses are given on a 7- 
point scale and the overall score is the mean of the responses (0 = totally controlled, 6 
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= severely uncontrolled). If a patient has an overall score of above 1.50, his asthma is 
poorly controlled and requires medical attention. 
 
MINI ASTHMA QUALITY OF LIFE QUESTIONNAIRE (MiniAQLQ): To 
assess the quality of life of patients. This is a miniature version of a 32-item Asthma 
Quality of Life Questionnaire(AQLQ). The miniature version also had good 
measurement properties and was validated. This questionnaire comprises of questions 
from five different domains. That is symptoms, environment, emotions and activities. 
It is having  7 point scaling in which a value ‘1’ signifies worst possible quality of life 
and a value ‘7’ signifies a normal quality of life. Individuals with low MiniAQLQ 
values have poor quality of life and their asthma will be poorly controlled, they will 
require medical attention. 
 
STUDY PROTOCOL: 
SELECTION OF PATIENT 
 Patient who has been diagnosed with uncontrolled severe persistent asthma 
with the following criteria: 
 Uncontrolled severe persistent asthma, under the use medications (ICS/OCS 
plus LABA). 
 Patient having an FEV1 less than or equal to 60% of predicted in the 
Pulmonary Function Test (PFT). 
 Patients who meet with the inclusion criteria are selected. 
 
FIRST VISIT: 
 In the first visit the patients pulmonary function report is being analysed and 
their FEV1 is observed and if there was a severe exacerbation an emergency 
medications to regulate the symptoms are given for 5-7 days. The patients where 
asked questions related to their asthma severity and control (ACQ) and also related to 
their quality of life (MiniAQLQ) and scorings were given correspondingly. After that 
the patient is prescribed with Tiotropium as a step-up therapy with ICS. LABA is also 
prescribed as a rescue medication that is to be taken in any case of emergency. The 
therapy will be given for period of 3 months. 
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FOLLOW UP: 
 Review of the patient is done 3 months after the initiation of drug 
(Tiotropium). In between the patient’s condition is being enquired by contacting the 
patient in phone. The patient is subjected for a PFT and the percentage of FEV1 is 
noted. The patients where asked questions related to their asthma severity and control 
(ACQ) and also related to their quality of life (MiniAQLQ) and scorings were given 
correspondingly. 
 
STATISTICAL ANALYSIS:  
 Demographic details, comorbidities, lung function values, adverse effect, 
FEV1, ACQ and MiniAQLQ were analyzed by using percentage of the frequency. The 
student‘t’ test was used to analyze the difference in scores at review after 3 months. A 
p Value of <0.05 shows significance. 
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5. TABLES AND GRAPHS 
Table 1: Shows the distribution of the gender among the study group (n = 70). 
 
 
 
 
 
 
 
 
 
 
Figure 5: Shows the graphical representation of the distribution of gender among the study 
population (n = 70). 
 
GENDER FREQUENCY PERCENTAGE 
Male 47 67.1 
Female 23 32.9 
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Table 2: Shows the age distribution in the study population (n = 70) 
 
 
 
 
 
 
 
 
 
Figure 6: Shows the graphical representation of distribution of age among the study 
population (n = 70). 
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AGE FREQUENCY PERCENTAGE 
11-20 1 1.4 
21-30 2 2.9 
31-40 5 7.1 
41-50 12 17.1 
51-60 12 17.1 
61-70 20 28.6 
71-80 16 22.9 
81-90 2 2.9 
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Table 3: Shows the occupation of study population (n = 70) 
 
 
 
 
 
 
 
 
 
Figure 7: Shows the graphical representation of occupation of the study population and 
their frequency (n = 70) 
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cotton mills ,textiles, industry, 
automobile workshop 
42 60.0 
agriculture, farmer 13 18.6 
others 15 21.4 
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              Table 4: Shows the smoking status of the study population (n = 70) 
 
   
                    Figure 8: Shows the smoking status of the study population (n = 70) 
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SMOKING STATUS FREQUENCY PERCENTAGE 
past 13 18.6 
never 57 81.4 
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Table 5: Shows the frequency of comorbidities present in the study population (n = 70) 
 
 
 
Figure 9: Shows the graphical representation of the frequency of comorbid conditions 
present in the study population (n = 70) 
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COMORBIDITY FREQUENCY PERCENTAGE 
NIL 18 25.7 
heart burn 21 30.0 
GERD 31 44.3 
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Table 6: Shows the range of FEV1 for the study population before the initiation of 
Tiotropium, scores are depicted in the bracket (n= 70) 
 
 
 
Figure 10: Shows the graphical representation of the FEV1 of the study population before 
the initiation of Tiotropium (n= 70) 
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69%-60% (4) 3 4.3 
59%-50% (5) 52 74.3 
<50% predicted (6) 15 21.4 
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Table 7: Shows the range of FEV1 for the study population after the initiation of 
Tiotropium, scores are depicted in the bracket (n= 70) 
 
 
Figure 11: Shows the graphical representation of the FEV1 of the study population after the 
initiation of Tiotropium (n= 70) 
7.1
75.7
11.4
5.7
0
10
20
30
40
50
60
70
80
3 4 5 6
PE
R
C
E
N
TA
G
E
SCORES
SCORES FREQUENCY PERCENTAGE 
79-70% (3) 5 7.1 
69-60% (4) 53 75.7 
59-50% (5) 8 11.4 
<50% PREDICTED (6) 4 5.7 
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Table 8: Shows the ACQ mean range among the study population before the initiation of 
Tiotropium, scores are depicted in the bracket (n= 70) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Shows the graphical representation of the ACQ mean among the study 
population before the initiation of Tiotropium (n= 70). 
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Table 9: Shows the ACQ mean range among the study population after the initiation of 
Tiotropium, scores are depicted in the bracket (n= 70) 
  
 
Figure 13: Shows the graphical representation of the ACQ mean among the study 
population after the initiation of Tiotropium (n= 70) 
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Very slightly uncontrolled (1) 10 14.3 
Slightly uncontrolled (2) 27 38.5 
Moderately uncontrolled (3) 28 40 
Difficult (4) 4 5.7 
Very difficult (5) 1 1.4 
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Table 10: Shows the distribution of mean value, standard deviation, standard error mean 
and p value for the ACQ: Before & After 
 
 
 
 
 
 
 
 
 
GROUP BEFORE & AFTER MEAN STD.DEVIATION 
STD.ERROR 
MEAN 
p 
VALUE 
Pair 1 
WOKEN UP BY 
ASTHMA 
3.043 1.148 .137 .000 
Pair 2 
ASTHMA 
SYMPTOMS 
2.971 1.351 .161 .000 
Pair 3 
ACTIVITY 
LIMITATION 
2.486 1.100 .131 .000 
Pair 4 
SHORTNESS OF 
BREATH 
2.643 1.036 .124 .000 
Pair 5 WHEEZE 2.571 1.124 .134 .000 
Pair 6 
SHORT ACTING 
BRONCHODILATOR 
1.843 .973 .116 .000 
Pair 7 FEV1 1.014 .525 .063 .000 
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Table 11: shows the AQLQ mean value among the study population before the initiation of 
Tiotropium, scores are depicted in the bracket (n= 70) 
 
 
SCORES 
 
FREQUENCY 
 
PERCENTAGE 
Very very difficult (1) 5 7.1 
Very difficult (2) 30 42.8 
Difficult (3) 27 38.5 
Moderately difficult (4) 8 11.4 
 
 
Figure 14: Shows the graphical representation of the AQLQ mean among the study 
population before the initiation of Tiotropium (n= 70) 
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Table 12: shows the AQLQ mean value among the study population after the initiation of 
Tiotropium, scores are depicted in the bracket (n= 70) 
SCORES FREQUENCY PERCENTAGE 
Difficult (3) 3 4.2 
Moderately difficult (4) 16 22.9 
Slightly difficult (5) 32 45.7 
Very slightly difficult(6) 18 25.7 
No problem(7) 1 1.4 
 
 
Figure15: Shows the graphical representation of the AQLQ mean among the study 
population after the initiation of Tiotropium (n= 70) 
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Table 13: Shows the distribution of mean value, standard deviation, standard error mean 
and p value in AQLQ: Before & After 
 
Domains Group Before & After MEAN Std. 
Deviation 
Std. Error 
Mean 
p Value 
SYMPTOMS PAIR -1 SHORT OF BREATH 2.500 1.052 .125 .000 
PAIR -4 COUGHING 2.914 1.239 .147 .000 
PAIR -6 CHEST TIGHTNESS 2.957 .885 .105 .000 
PAIR -8 GOOD NIGHT SLEEP 3.100 .943 .112 .000 
PAIR -10 WHEEZE 2.729 1.041 .124 .000 
ENVIRONME
NTAL 
PAIR -2 DUST 2.329 1.204 .143 .000 
PAIR -7 CIGARETTE SMOKE 2.314 1.178 .140 .000 
PAIR -11 AIR POLLUTION 2.614 1.125 .134 .000 
EMOTIONAL PAIR -3 FRUSTRATED 2.471 1.065 .126 .000 
PAIR -5 ASTHMA 
MEDICATION 
2.200 1.440 .171 .000 
PAIR -9 CONCERNED 2.671 1.306 .155 .000 
ACTIVITY 
LIMITATION 
PAIR -12 STRENOUS 
ACTIVITIES 
1.186 .946 .112 .000 
PAIR -13 MODERATE 
ACTIVITIES 
2.229 .848 .101 .000 
PAIR -14 SOCIAL ACTIVITIES 2.514 1.156 .137 .000 
PAIR -15 WORK-RELATED 
ACTIVITIES 
2.557 .966 .115 .000 
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Table 14: Shows the distribution of mean value, standard deviation, standard error mean 
and p value in ACQ and AQLQ: Before & After 
 
 
 
  
Pairs Before & After Mean Std. Deviation Std Error Mean p Value 
Pair 1 
TOTAL MEAN 
ACQ 
2.414 .876 .105 .000 
Pair 2 
TOTAL MEAN 
AQLQ 
2.386 .839 .100 .000 
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Table 15: Shows the frequency of adverse effect occurred in the study population (n = 70) 
 
 
 
 
Figure 16: Shows the graphical representation of the frequency of adverse effect 
occurrence in the study population (n = 70) 
Adverse effect Frequency Percentage 
yes 5 7.1 
no 65 92.9 
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6. RESULTS  
 A total of 70 patients with poorly controlled asthma were analyzed for the study. 
Among them 47 (67.1%) were males and 23 (32.9%) were females. This is depicted in table 1 
and figure 5. 
 The total number of patients (n=70) were categorized into different age groups. Lowest 
age being 18 and highest age group is 81-90. The patients falling in each category of age group 
is depicted in the table 3 and figure 6 and from the results obtained through the study it was 
analyzed that patients in the age group 61-70 were affected more and was diagnosed as poorly 
controlled asthmatic patients, that is 20 (28.6%) of the total patients. This was followed by the 
age group 71-80, which contributed about 16 (22.9%) of the total number of patients. 
Individuals less than 40 years of age was least diagnosed as poorly controlled asthmatic 
patients. Elderly people were found to be more affected by uncontrolled asthma and was 
diagnosed as poorly controlled asthmatic patient. 
 
 The effect of occupation on the individual’s disease status was assessed during the 
study, it is depicted in table 3 and figure 7 and it was found that the majority of patients who 
had poorly controlled asthma was having a continuous exposure towards allergens. They 
contributed about 42 (60.0%) out of 70 patients. Followed by farmers who were exposed to 
mites and pollens 13 (18.6%) out of 70 patients, both of this category were exposed towards 
their occupational allergens and they were advised to change their occupation if possible and 
if not to use mask and other preventive measure and there by avoid the exposure towards the 
allergens to maximum possible. Other professionals contributed 15 (21.4%) out of 70. 
 
 Smoking always had a negative effect over the respiratory system. Chain smokers 
mostly developed chronic obstructive pulmonary disorder (COPD). Sometimes it can also have 
an effect on asthmatic patients and can be the reason for their poor adherence. Therefore it was 
also analyzed during the study, it is depicted in table 4 and figure 8 and from the observations 
it was found that the majority of the diagnosed poorly controlled asthma patient were not 
because of smoking. Majority of patients were not having a habit of smoking. A total of 57 
(81.4%) patients were nonsmoker’s only. 12 (18.6%) patients had a past history of smoking 
and it was expected to be the reason for their poor adherence and poor control over asthma. 
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 Since all patients were diagnosed for asthma long before and were under asthma 
medication. The comorbidity present in patients were also assessed during the study, it is 
depicted in table 5 and figure 9 and it was found that 31 out of 70 (44.3%) patients had gastro 
oesophageal reflux disorder (GERD) and 21(30.0%) out of the 70 had heart burn, which is a 
symptom of GERD but they were not having confirmed diagnosis of GERD. Only 18(25.7%) 
was found to be absent from any of the comorbities. The presence of comorbidity affected the 
quality of life and they were supposed to take medications for the respective comorbidities.  
 
 Forced expiratory volume (FEV1) is an important marker in categorizing asthma based 
on severity, the patients whose FEV1 was 60% or less than that, in spite of drugs intake 
(ICS/OCS+ LABA) was considered as having poorly controlled asthma as per the guidelines. 
The patients with poorly controlled asthma was selected for the study based on this criteria and 
from the study it was analyzed that 52 (74.3%) patients had an FEV1 ranging between 59%-
50%. And 15 patients had FEV1 falling less than 50% while 3 of them falls in the category 60-
69% (4.3%) during the first visit. It is depicted in table 6 and figure 10. 
 
 In the second review it was observed that after the administration of Tiotropium 
bromide as a step-up therapy along with corticosteroids ,53 (75.7%) patients showed 
improvement in their pulmonary function test (PFT) and 53 (75.7%) patients improved and 
fallen in range of 69-60%, followed by 8(11.4%) fallen in the range of 59-50%,followed by 
5(7.1%) has been in the category of 79-70% while 4 patients was in the category of >50% of 
predicted FEV1 values. It is depicted in the table 7 and figure 11.  
Thus it showed significant improvement in the FEV1 value from first visit to the second visit 
which was after 3 months. 
 On assessing the Asthma Control Questionnaire (ACQ) mean during the first visit it 
was found that 33 (47.2%) out of 70 have very difficult severely uncontrolled asthma, followed 
by 22 (31.4%) had difficultly uncontrolled asthma, 13(18.6%) out of 70 patients had severely 
uncontrolled asthma. Table 8 and figure 12 shows this.  
 It was compared with the review which was 3 months after the initiation of Tiotropium 
bromide along with corticosteroids as a step-up therapy. And in the review it was observed that 
only a single (1.4%) patient was with very difficult uncontrolled asthma, while 28 (40%) 
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patients came in the category of moderately uncontrolled asthma and 27 (38.5%) came in the 
category of slightly uncontrolled asthma while 10 (14.3%) out of 70 has improved towards 
very slightly uncontrolled asthma. The number of patients with difficultly uncontrolled severe 
asthma was reduced to 4 (5.7%). Table 9 and figure 13 shows this.  
There found to be significant improvement over the asthma severity and control over asthma 
in patients. 
 Asthma quality life was also assessed for all the patients. while assessing the Asthma 
Quality of Life Questionnaire (AQLQ) total mean of patient before starting Tiotropium 
bromide it was observed that 30 (42.8%) out of 70 had a very poor quality of life, followed by 
27 (38.5%) had difficultly poor quality of life.8(11.4%) had moderately difficult quality of life 
and 5 (7.1%) had worst possible quality of life. This is depicted in the table 11 and figure 14. 
When it was compared with the AQLQ total mean in the review which was 3 months after 
initiation of Tiotropium bromide, 32(45.7%) improved towards slightly difficult quality of life, 
followed by 18(25.7%) improved towards very slightly difficult quality of life, followed by 
16(22.9%) has improved towards moderately difficult quality of life, the number of individuals 
in the difficultly poor quality of life has reduced to 3 (4.2%). Single patient has shown 
improvement and he was not having any problem with his quality of life. It is depicted in table 
12 and figure 15. 
 The AQLQ analysis also showed significant improvement in patients when compared 
the pre and post data’s. This showed the usefulness of Tiotropium in patients with poorly 
controlled asthma as a step-up therapy was also analyzed during the study.  
It is depicted in table 15 and figure 16. It is observed that only 5(7.1%) out of 70 patients 
developed dry mouth and the remaining 65 (92.9%) did not report any adverse effect or 
difficulty due to the intake of Tiotropium bromide.   
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8. DISCUSSION 
 In this study we present the data that shows the usefulness of Tiotropium bromide in 
poorly controlled asthma by showing its positive effect on spirometry performed. This study 
also provides evidence for the improvement in the asthma control by using the Asthma Control 
Questionnaire (ACQ) and the improvement in the quality of life of patient using the Asthma 
Quality of Life Questionnaire (AQLQ). The occurrence of any adverse effect due to the 
initiation of Tiotropium bromide in patients is also monitored. 
 Out of 70 poorly controlled asthmatic patient included in the study, 47 (67.1%) were 
males and 23 (32.9%) were females. 
  Stephen P. Peters26 in his study which is analyzing the efficiency of Tiotropium 
bromide as a step- up therapy for adults with uncontrolled asthma, 32.9% were males and 
67.1% were females. Elizabeth F. Juniper28 conducted a study and in their study 45.1% was 
males and 54.89% was females who were affected by severe persistent asthma.  Huib A. M. 
Kerstjens14 conducted a study to analyze whether Tiotropium improves ling function in patients 
with severe uncontrolled asthma and in the study it says that 54.2% were females and 45.8% 
males were affected with severe uncontrolled asthma. In this epidemiology, since there were 
more men going for work in textiles and all, and so they were having more poorly controlled 
asthma and exacerbations. Therefore in this study more number of patients were males. 
 In this study more number of patients with poorly controlled asthma was observed in 
age group 40-80.Stephen P. Peters26 in his study the mean age was found to be 42.2 ± 
12.3.Elizabeth F. Juniper28 conducted a study and in their study the mean age was found to be 
44.7.Eric D. Bateman13 conducted a study and in that the mean age was found to be 53.5 ± 
12.6. Huib A. M. Kerstjens14 conducted a study and in that the mean age was found to be 54.8 
± 11.7. Pierluigi Paggiaro18 conducted a study and in that the mean age was found to be 42.9 ± 
13.0. Ke Wangl19 conducted a study and the mean age was 36.4 ± 5.93. 
 In this study 78.6% of patients were having poorly controlled asthma because of their 
exposure towards occupational asthmogens (60.0% were exposed to the cotton dust, textiles 
and other industrial allergens, while 18.6% were exposed to allergens from farms and 
agriculture).  Nicole Le Moual29 conducted a study on asthma severity and exposure to 
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occupational asthmogens and in their study they found that 61.2% of people were suffering 
from uncontrolled severe persistent asthma because of continuous exposure towards 
occupational asthmogens. Studies conducted on occupational asthma and the asthmogens45, 47, 
says that trigger factors to severe asthma include occupational agents. 
 In this study the smoking status of the patients were analyzed and it was found that 
81.4% of patients were not having a habit of smoking, while 18.6% patients were having a past 
history of smoking. And from our study we observed that a habit of smoking can lead to poor 
control over asthma and poor compliance towards the medication and it can also cause 
worsening of the asthma status of the patient. But in this study not the majority of patients were 
having poorly controlled severe persistent asthma because of the smoking status, there reasons 
are different. But for 18.6% of people who had a past history of smoking, it paved the way 
towards poor control over asthma even under medications. Eric D. Bateman13 conducted a 
study, in this 69.5% patients never smoked, 30.5% were ex-smokers. No one was having a 
habit of smoking at present. In this study they mention that smoking is having a negative impact 
in attaining appropriate asthma control. In order to attain an optimum asthma control smoking 
should be stopped. Dejan Radovanovic12 conducted a study in this it is specified that cigarette 
smoke is one among the factors that can induce airway inflammation and there by chronic 
airway inflammation can lead to airway remodelling also. Huib A. M. Kerstjens14 conducted a 
study, in this 68.2% of patients with poorly controlled asthma never smoked while 31.8% 
patients were ex-smokers. Pierluigi Paggiaro18 conducted a study and in this 78.7% individuals 
never smoked while 21.3% individuals were ex-smokers. This study shows that Tiotropium 
improved the mean lung function parameter responses from baseline to week 12 for both non-
smokers, ex-smokers. 
 In this study the patients without comorbidity was only 18 (25.7%) while the majority 
was having comorbidity 52 (74.3%). In which 31 (44.3%) patients were having Gastro 
Oesophageal Reflux Disorder (GERD), while 21 (30.0%) patients were having heart burn, 
which shows patients symptomatic for GERD. Susan. M . Harding46 conducted a study and in 
the study it says that 62% of asthma patients were having GERD as a comorbidity. The 
relationship between the worsening of the disease in severe asthmatic patients due to GERD 
has been explained in this study convincingly. Francois Vermeulen24 conducted a study and in 
this study it says that 34.0% patients with uncontrolled asthma were having GERD as a 
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comorbid condition. Carla Bisaccioni43 conducted a study and evaluated the frequency of 
comorbidities. And in this study it states that patients with GERD symptoms were reported 
about 70.6% (173), though patients confirmed with the GERD diagnosis was 58 (33.6%) 
patients. 
 In my study severe uncontrolled asthma patients were selected based on their FEV1 
value as the major criteria, which was mentioned in the GINA guidelines to identify the severe 
uncontrolled asthma. As per the guidelines the patients who have an FEV1 value less than or 
equal to 60% of predicted, while already under medications as per in the guidelines are 
considered as patients with uncontrolled severe persistent asthma patients. In my study all such 
patients were selected that is patients who had an FEV1 equal to or less than 60% of predicted. 
Majority of patients that is 74.3% (52) were falling under the range of 59-50%, this range is 
given a score 5 in the asthma control questionnaire which out of 6 and it indicates a very 
difficultly uncontrolled persistent asthma. 21.4% (15) patients were in the category of FEV1 
less than 50% predicted which was given a score of 6 as per the asthma control questionnaire 
scoring scale and it indicated severely uncontrolled persistent asthma for such patients. 4.3% 
(3) of patients had a 60% of predicted FEV1, and this was given a score of 4 as per the asthma 
control questionnaire which indicated difficultly uncontrolled persistent asthma.  
 After the initiation of Tiotropium bromide (18µg) as once daily dose taken in the 
afternoon for 12 weeks, spirometry was performed and the FEV1 was analyzed. All the patients 
had improvement in their control over asthma and the severity of the disease, majority had a 
significant improvement while a few had only a slight improvement. But there was difference 
in all the patients’ disease status after the initiation of the therapy. Majority of patient in the 
post examination 75.7% (53) had fallen in the category of 69-60% which was given a score 4 
as per the asthma control questionnaire which indicated difficultly uncontrolled asthma. This 
showed a significant improvement in the FEV1 value from pre towards the post on initiation of 
Tiotropium bromide. 11.4% (8) were in the category 59-50% which was given a score 5 as per 
the asthma control questionnaire scoring which indicated a very difficultly uncontrolled 
persistent asthma. 7.1% (5) patients were having a FEV1 in the range of 79-70% which was 
given a score 3 as per the asthma control questionnaire scoring which indicated moderately 
uncontrolled persistent asthma. 5.7% (4) had a FEV1 less than 50% of predicted which was 
given a score of 6 as per the asthma control questionnaire which indicated severely uncontrolled 
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asthma patients. The post analysis of patients showed improvement after a 12 week therapy of 
Tiotropium bromide, individuals were having response towards the drug. 
 Huib A. M. Kerstjens14 conducted a study in this, it states that the addition of once daily 
dose of Tiotropium as a maintenance therapy along with ICS and LABA in patients with severe 
uncontrolled asthma significantly improves lung function. Tiotropium was superior when 
compared with all other spirometric assessments. Pierluigi Paggiaro18 conducted a study in this, 
it states that Tiotropium is an efficacious bronchodialator when added to low to medium dose 
ICS. Ke Wang19 conducted a study,in this study Tiotropium bromide a dose of 18µg was 
administered  to one of the groups as a once daily dose ,for a period of 12 weeks and was found 
from the study that Tiotropium in combination with ICS  plus LABA was efficient to provide 
an optimum control over asthma equivalent to that of doubling the dose of ICS plus LABA 
without causing any adverse effects. So it was found to be the best second line treatment for 
patients with uncontrolled moderate asthma patients. Stephen P. Peters26 in his study in this it 
was found that Tiotropium when added to an ICS it improved the lung function (FEV1) in 
patients with inadequately controlled asthma. And the effect produced by Tiotropium was 
superior when compared with doubling the dose of ICS and was equivalent to the effect of 
LABA. 
 In my study to identify well and not well controlled asthma and to determine the 
severity of asthma the asthma control questionnaire (ACQ) is being used. The asthma control 
questionnaire (ACQ) consist of 7 questions. This questionnaire is short one, which comprises 
of questions related to symptoms which is considered to be the most important in assessing the 
asthma sufficiency of asthma control. Questions related to the use of short acting ß2 agonist as 
a rescue medication. Question on the pulmonary function test of the patient. And ACQ has 
scoring system in 7- point scale, 0 is indicative of totally controlled while 6 is indicative of 
severely uncontrolled. 
 In my study majority of patients were having poor control over asthma and they were 
suffering because of the disease in the first visit. That is majority of patients was found to have 
very difficultly uncontrolled asthma, they were having a score 5 as per the ACQ, 47.2% (33) 
patients were in this category. 31.4% (22) patients were having a score 4 which indicated 
difficultly uncontrolled asthma as per the ACQ. 18.6% (13) were having a score 6 through 
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ACQ which indicated a severely uncontrolled persistent asthma. 2.8% (2) were having a score 
3 through ACQ which indicated moderately uncontrolled asthma. 
 After the initiation of Tiotropium bromide (18µg) as once daily dose for a duration of 
12 weeks and then the patients were assessed using the ACQ and given scoring. 40% (28) of 
patients were given a score 3 which indicated moderately uncontrolled asthma. 38.5% (27) 
were given a score 2 through ACQ which indicated slightly uncontrolled asthma. 14.3% (10) 
were given a score 1 through ACQ which indicated very slightly uncontrolled asthma. 5.7% 
(4) were given a score 4 through ACQ which indicated difficultly uncontrolled asthma. 1.4% 
(1) was given a score 5 through ACQ which indicated very difficultly uncontrolled asthma. 
None of the patients has fallen in the category of severely uncontrolled asthma after the 
initiation of therapy, there was improvement in the total mean score of ACQ for each patient, 
which indicated an improvement in their symptoms, use of rescue medication and the lung 
function. This also showed that patients were having a good response towards the drug. 
  Stephen P. Peters26 in his study which is analyzing the efficiency of Tiotropium 
bromide as a step- up therapy for adults with uncontrolled asthma, in this study it is showed 
that the addition of Tiotropium to an ICS showed improvement in the ACQ score of patient 
which had significance (p value <0.001). This study also stated that the Tiotropium as step-up 
therapy with ICS had a superior outcome than doubling the dose of ICS. Ke Wang19 conducted 
a study to evaluate the best second line treatment for uncontrolled moderate asthma patients 
maintenance therapy whose asthma is not fully controlled, mild to moderate asthma. In this 
study Tiotropium bromide a dose of 18µg was administered to one of the groups as a once daily 
dose,for a period of 12 weeks and was found from the study that Tiotropium in combination 
with ICS  plus LABA showed significant improvements in symptom control, FEV1,reduce the 
risk of acute exacerbation and thereby has shown a significant improvement in the ACQ score 
after the initiation of drug.  Pierluigi Paggiaro18 conducted a study to analyze the effect of 
Tiotropium in asthmatic patients despite the use of low to medium dose of inhaled 
corticosteroids and in the study it stated that there was an improvement in the ACQ score from 
baseline towards a period after 12 weeks treatment with the drug. That is from uncontrolled to 
partially uncontrolled with a dose of 5µg and 2.5µg of Tiotropium. This study provided that 
Tiotropium lead to an improved lung function and control in asthma and states that it is an 
effective bronchodialator. Jean Bousquet48 conducted a study to determine a cut- point on the 
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ACQ there by to differentiate between well controlled and not well controlled asthma, using 
ACQ. In the study it is said that if a patient have an ACQ score of 1.50 or greater, there is an 
88% chance that his or her asthma is not well controlled. A change in ACQ score by 0.5 shall 
be considered clinically important.  
  MiniAQLQ was being used in my study and there the quality of life of patient with 
severe uncontrolled asthma were measured and their difference in the quality of life after the 
initiation of therapy was analyzed and assessed. The original AQLQ was a 32-item 
questionnaire which consisted of four domains: symptoms (12 items), activity limitation (11 
item), emotional function (5 item) and environmental stimuli (4 items), since it was a pretty 
difficult to assess all this in large surveys their arised the need for the development of a shorter 
version of this but which was called as MiniAQLQ, which would construct measure the same 
construct and meet the same specification as that of the original AQLQ. MiniAQLQ also 
consisted of the four domains: symptoms (5 items), activity limitation (4 items), emotional 
function (3 items) and environmental stimuli (3 items). MiniAQLQ had 7 point scoring scale, 
in which 1- indicated worst possible quality of life and 7- indicated a normal quality of life (no 
problem).   During the initial visit majority 42.8% (30) of the patients had score 2 as per the 
AQLQ which was indicative of a very difficult quality of life. 38.5% (27) patients had a score 
of 3 as per the AQLQ which indicated a difficult quality of life. 11.4% (8) had a score 4 as per 
the AQLQ which indicated moderately difficult quality of life. 7.1% (5) had a score 1 as per 
the AQLQ which indicated a worst possible quality of life. 
 After the initiation of Tiotropium bromide 18µg as once daily dose for a period of 12 
week the AQLQ was measured and in that the majority of patients 45.7% (32) had a score 5 
which indicated slightly difficult quality of life as per AQLQ. 25.7% (18) had a score 6 as per 
AQLQ which indicated very slightly difficult quality of life. 22.9% (16) had a score 4 as per 
the AQLQ which indicated moderately difficult quality of life. 4.2% (3) had a score 3 as per 
the AQLQ which indicated difficult quality of life. 1.4% (1) patient had a score 7 as per the 
AQLQ which indicated normal quality of life (no problem). There showed an improvement in 
the quality of life of patient within a 12 weeks duration. None of the patients were in the 
category of worst possible and very difficult quality of life (1 and 2 respectively). The quality 
of life of patients showed improvement with the initiation of therapy.    
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 Stephen P. Peters26 in his study which is analyzing the efficiency of Tiotropium 
bromide as a step- up therapy for adults with uncontrolled asthma, in this study it is showed 
that the addition of Tiotropium to an ICS showed improvement in the MiniAQLQ of the 
patients and showed significance (p value = 0.01). Stacy J. Chin49 conducted a commentary on 
5 clinical trials in adults on the effect of Tiotropium for the treatment of asthma. In this study 
it states administration of Tiotropium lead to improvement in the quality of life. Huib A. M. 
Kerstjens14 conducted a study to analyze whether Tiotropium improves lung function in 
patients with severe uncontrolled asthma. In this study it is stated that the MiniAQLQ scores 
over the entire treatment period of 0.1 points for both the active treatments when compared 
with placebo. There is no significant improvement in the quality of life. The dose of Tiotropium 
was 5 and 10µg respectively for a period of 8 weeks. 
 On statistical analysis of the asthma control questionnaire (ACQ) for all the 7 asthma 
control questions pre and post, significance was observed (p=.000) with respect to a standard 
deviation ± mean. Pair 1 (woken up by asthma) had 1.148 ± 3.043, p value = .000, Pair 2 
(asthma symptoms) had 1.351 ± 2.971, p value = .000, Pair 3 (activity limitation) had 1.100 ± 
2.486, p value = .000. Pair 4 (shortness of breath) had 1.036 ± 2.643, p value = .000. Pair 5 
(wheeze) had 1.124 ± 2.571, p value = .000. Pair 6 (short acting bronchodilator) had .973 ± 
1.843, p value = .000. Pair 7 (FEV1) had .525 ± 1.014, p value =.000  
 On the statistical analysis of the Mini asthma quality of life questionnaire (MiniAQLQ) 
when compared the pre and the post quality of life significance was obtained with respect to 
standard deviation ± mean for the 15 questions which consisted of four domains. 
  Domain -1(symptoms): pair 1(short of breath) had 1.052 ± 2.500, p value .000. Pair 4 
(coughing) had 1.239 ± 2.914, p value = .000. Pair 6 (chest tightness) had .885 ± 2.957 .p value 
= .000. Pair 8 (good night sleep), had .943 ± 3.100, p value = .000. Pair 10 (wheeze) 1.041 ± 
2.729, p value = .000. 
 Domain -2 (environmental): Pair 2 (dust) had 1.204 ± 2.329, p value = .000. Pair 7 
(cigarette smoke) had 1.178 ± 2.314, p value =.000. Pair 11(air pollution) had 1.125 ± 2.614, 
p value = .000.  
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 Domain – 3(emotional): Pair 3 (frustrated) had 1.065 ± 2.471, p value = .000. Pair -5 
(asthma medication) had 1.440 ± 2.200, p value = .000. Pair – 9 (concerned) 1.306 ± 2.671,p 
value = .000. 
 Domain – 4 (activity limitation): Pair – 12 (strenuous activities) had .946 ± 1.186, p 
value = .000. Pair – 13 (moderate activities) had .848 ± 2.229, p value = .000. Pair – 14 (social 
activities) had 1.156 ± 2.514, p value = .000. Pair-15 (work related activities) had .966 ± 2.557, 
p value = .000. 
 On statistical analysis of the total mean of ACQ and AQLQ: we obtained a result that 
is total mean ACQ (pre & post) .876 ± 2.414 (standard deviation ± mean), p value = .000. Total 
mean AQLQ (pre & post) .839 ± 2.386 (standard deviation ± mean), p value = .000. Both for 
ACQ and AQLQ total mean (pre & post) significance was observed. 
 In this study drug induced adverse effects were assessed and only dry mouth was 
reported, and even it was with a very minimum number of patients. That is 7.1% (5) patients 
reported dry mouth while 92.9 % (65) didn’t report any adverse effects. This indicated that 
Tiotropium was not having any serious adverse effects on the patients, and it is safe for use. 
Michael Engel25 conducted a study in this study it is stated that dry mouth was reported in less 
than 2% of all patients and was reported more frequently in Tiotropium group than in the 
placebo group. It was a known adverse event of Tiotropium (anticholinergic).  Huib A. M. 
Kerstjens14 conducted a study in this study it states that 6.8% (7) with Tiotropium reported dry 
mouth, in patients with 10µg of Tiotropium. While in Tiotropium 5µg dose was given, only 
1.9% (2) reported dry mouth. 
 Studies conducted on safety of Tiotropium18,50 , says that adverse events leading to 
discontinuation of the therapy was infrequently reported and it stated that Tiotropium was safe 
and well tolerated. 
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6. CONCLUSION 
 In this retrospective and prospective study, the patients were having very poor 
asthma control (uncontrolled severe persistent asthma) and correspondingly their quality 
of life was also very poor at the baseline. The patients were already on ICS and stepping 
up the therapy can cause adverse effects. So Tiotropium was found as an efficacious step – 
up therapy for poorly controlled asthma patients. After the initiation of Tiotropium 
bromide as a step up therapy along with ICS there found improvement in the patient 
control over asthma and also their quality of life. The initiation of Tiotropium improved 
the lung function of patients and the drug was safe to be taken and well tolerated. Only a 
very small percentage reported adverse effect,that too was not serious. Though some 
studies have been done on this, but the use of Tiotropium has not yet been done in the 
daily life. Therefore more large studies should be done to give more authenticity towards 
this small study regarding the usefulness of Tiotropium in severe persistent uncontrolled 
asthma patients, who are already under ICS and LABA.  
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DATA COLLECTION FORM 
 
 
IP/OP. No.:                                                                                  DATE: 
NAME:                     AGE:                      SEX: 
WEIGHT:                     HEIGHT:    BMI:                     ADDRESS: 
OCCUPATION:          
DIET: VEG/ NON-VEG 
SOCIAL HABITS – ALCOHOL                     - present / past / never        
                                 SMOKING/ TOBACCO - present / past / never 
PAST MEDICAL & MEDICATION HISTORY: 
COMORBIDITIES: 
PRESENT COMPLAINTS: 
Have you been treated before for the same complaints: 
 
 
     
 
 
Symptom Severity Scale: 
 
 
 
 
 
 
Sl. 
No SYMPTOMS 
YES/
NO DURATION 
SEVERITY SCALE (DAY 1) 
MILD 
 
MODERATE 
 
SEVERE 
 
1 Night time awakening      
2 
Short acting ß2 
adrenergic agonist used 
for symptom control 
     
3 
Interference with 
normal activity: 
 Breathlessness 
 Talks in 
 Alertness 
     
4 Lung function (spirometry)      
5 Requirement of oral steroid in past 1 year      
6 No:of exacerbation in past 1 year      
7 Heart burn      
8 Previous medication      
  
 
 
 
 
Sl. 
No SYMPTOMS YES/NO DURATION 
SEVERITY SCALE  
MILD 
 
MODERATE 
 
SEVERE 
 
1 Night time awakening      
2 
Short acting ß2 
adrenergic agonist 
used for symptom 
control 
     
3 
Interference with 
normal activity: 
 Breathlessness 
 Talks in 
 Alertness 
     
4 Lung function (spirometry)      
5 Requirement of oral steroid in past 1 year      
6 No:of exacerbation in past 1 year      
7 Heart burn      
8 Previous medication      
  
OVERALL TREATMENT EFFICACY (OTE) SCALE: 
 
ON FIRST DAY: 
 
 
 
 
 
 
 
 
AFTER  
  
   
  
